Liver Disease Treatments: The Global Market

Abstract

BCC' s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for liver diseases treatments. The report determines the market size and market leaders, provides a market overview, and examines factors affecting the markets for drugs used to treat liver diseases. The markets have been defined by disease type and by drug type. The overview of types of liver diseases, their symptoms and their treatments is examined along with sales figures over the five-year period from 2009 to 2014. The report also gives the demand and use criteria of the drugs used to treat liver diseases, as well as an overview of drug-induced liver diseases. Companies manufacturing and selling the drug products in this category are profiled, and factors affecting markets for these products and how the markets are likely to change are analyzed. Revenues have been broken down by the type of diseases and by different regions. Our key objective is to present a comprehensive analysis of the current market and the future direction of the drugs used to treat liver diseases.

The scope of this study encompasses the market for liver disease treatments. BCC analyzes each market and its leaders, the different types of liver diseases, the different types of drug products to treat liver diseases, the regulatory environment, the regional market for liver diseases and the drug products used to treat them, and market projections and market share. Technological issues include latest trends and new developments.

• The global market for liver disease treatments amounted to nearly $8.4 billion in 2007 and is expected to increase to $9.8 billion in 2014, for a compound annual growth rate (CAGR) of 3.0%
• The treatment for hepatitis is the largest segment of the market, amounting to about $4.6 billion in the last three years, and is expected to reach $4.8 billion in 2014.
• Sales of targeted therapies were comparatively less in 2008, but this market has the potential to grow faster mainly because of the increased incidence of hepatitis C in developing countries.

A combination of primary and secondary research methods were used in this study. A comprehensive search of literature was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/ biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.

BCC surveyed many companies to obtain data for this study. Included were manufacturers and the end users of the drugs used to treat liver diseases. We gathered industry data, spoke with officials from this industry, and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.